• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

发现 P2X2 受体的有效竞争性拮抗剂和正向调节剂。

Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.

机构信息

PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, Pharmaceutical Sciences Bonn (PSB), University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.

出版信息

J Med Chem. 2011 Feb 10;54(3):817-30. doi: 10.1021/jm1012193. Epub 2011 Jan 5.

DOI:10.1021/jm1012193
PMID:21207957
Abstract

Evaluation and optimization of anthraquinone derivatives related to Reactive Blue 2 at P2X2 receptors yielded the first potent and selective P2X2 receptor antagonists. The compounds were tested for inhibition of ATP (10 μM) mediated currents in Xenopus oocytes expressing the rat P2X2 receptor. The most potent antagonists were sodium 1-amino-4-[3-(4,6-dichloro[1,3,5]triazine-2-ylamino)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (63, PSB-10211, IC(50) 86 nM) and disodium 1-amino-4-[3-(4,6-dichloro[1,3,5]triazine-2-ylamino)-4-sulfophenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (57, PSB-1011, IC(50) 79 nM). Compound 57 exhibited a competitive mechanism of action (pA(2) 7.49). It was >100-fold selective versus P2X4, P2X7, and several investigated P2Y receptor subtypes (P2Y(2,4,6,12)); selectivity versus P2X1 and P2X3 receptors was moderate (>5-fold). Compound 57 was >13-fold more potent at the homomeric P2X2 than at the heteromeric P2X2/3 receptor. Several anthraquinone derivatives were found to act as positive modulators of ATP effects at P2X2 receptors, for example, sodium 1-amino-4-(3-phenoxyphenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (51, PSB-10129, EC(50) 489 nM), which led to about a 3-fold increase in the ATP-elicited current.

摘要

评估和优化与反应性蓝 2 相关的蒽醌衍生物在 P2X2 受体上产生了第一个有效且选择性的 P2X2 受体拮抗剂。这些化合物在表达大鼠 P2X2 受体的非洲爪蟾卵母细胞中被测试了对 ATP(10 μM)介导电流的抑制作用。最有效的拮抗剂是 1-氨基-4-[3-(4,6-二氯[1,3,5]三嗪-2-基氨基)苯基氨基]-9,10-二氧代-9,10-二氢蒽-2-磺酸钠(63,PSB-10211,IC50 86 nM)和 1-氨基-4-[3-(4,6-二氯[1,3,5]三嗪-2-基氨基)-4-磺基苯基氨基]-9,10-二氧代-9,10-二氢蒽-2-磺酸钠(57,PSB-1011,IC50 79 nM)。化合物 57 表现出竞争性作用机制(pA2 7.49)。它对 P2X4、P2X7 和几种研究的 P2Y 受体亚型(P2Y(2,4,6,12))的选择性 >100 倍;对 P2X1 和 P2X3 受体的选择性适中(>5 倍)。化合物 57 在同型 P2X2 受体上的效力比在异型 P2X2/3 受体上高 13 倍以上。一些蒽醌衍生物被发现是 P2X2 受体上 ATP 效应的正调节剂,例如 1-氨基-4-(3-苯氧基苯基氨基)-9,10-二氧代-9,10-二氢蒽-2-磺酸钠(51,PSB-10129,EC50 489 nM),它导致 ATP 引发的电流增加约 3 倍。

相似文献

1
Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.发现 P2X2 受体的有效竞争性拮抗剂和正向调节剂。
J Med Chem. 2011 Feb 10;54(3):817-30. doi: 10.1021/jm1012193. Epub 2011 Jan 5.
2
Selective potentiation of homomeric P2X2 ionotropic ATP receptors by a fast non-genomic action of progesterone.孕酮通过快速非基因组作用对同型 P2X2 离子型 ATP 受体的选择性增强。
Neuropharmacology. 2010 Mar;58(3):569-77. doi: 10.1016/j.neuropharm.2009.12.002. Epub 2009 Dec 16.
3
Flexible subunit stoichiometry of functional human P2X2/3 heteromeric receptors.功能性人源P2X2/3异源寡聚体受体的灵活亚基化学计量比
Neuropharmacology. 2015 Dec;99:115-30. doi: 10.1016/j.neuropharm.2015.07.008. Epub 2015 Jul 13.
4
High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors.血小板P2Y12受体的高亲和力、非核苷酸衍生的竞争性拮抗剂。
J Med Chem. 2009 Jun 25;52(12):3784-93. doi: 10.1021/jm9003297.
5
P2X1 and P2X2 receptors in the central nervous system as possible drug targets.中枢神经系统中的 P2X1 和 P2X2 受体作为可能的药物靶点。
CNS Neurol Disord Drug Targets. 2012 Sep;11(6):675-86. doi: 10.2174/187152712803581128.
6
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.磷酸吡哆醛衍生物作为P2X1受体强效和选择性拮抗剂的构效关系
J Med Chem. 2001 Feb 1;44(3):340-9. doi: 10.1021/jm9904203.
7
Identification of aurintricarboxylic acid as a potent allosteric antagonist of P2X1 and P2X3 receptors.鉴定金顶侧耳酸为 P2X1 和 P2X3 受体的有效别构拮抗剂。
Neuropharmacology. 2019 Nov 1;158:107749. doi: 10.1016/j.neuropharm.2019.107749. Epub 2019 Aug 25.
8
Lithocholic acid inhibits P2X2 and potentiates P2X4 receptor channel gating.胆酸抑制 P2X2 并增强 P2X4 受体通道门控。
J Steroid Biochem Mol Biol. 2020 Sep;202:105725. doi: 10.1016/j.jsbmb.2020.105725. Epub 2020 Jul 8.
9
Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold.基于蒽醌骨架开发有效的、选择性的外核苷酸酶 5'- 抑制剂。
J Med Chem. 2010 Mar 11;53(5):2076-86. doi: 10.1021/jm901851t.
10
Molecular basis of selective antagonism of the P2X1 receptor for ATP by NF449 and suramin: contribution of basic amino acids in the cysteine-rich loop.NF449 和苏拉明对 ATP 作用的 P2X1 受体选择性拮抗的分子基础:富含半胱氨酸环中碱性氨基酸的作用。
Br J Pharmacol. 2012 Jan;165(2):390-400. doi: 10.1111/j.1476-5381.2011.01534.x.

引用本文的文献

1
Pharmacology of P2X Receptors and Their Possible Therapeutic Potential in Obesity and Diabetes.P2X受体的药理学及其在肥胖症和糖尿病中的潜在治疗作用
Pharmaceuticals (Basel). 2024 Sep 28;17(10):1291. doi: 10.3390/ph17101291.
2
Pharmacological interaction and immune response of purinergic receptors in therapeutic modulation.嘌呤能受体在治疗调节中的药物相互作用和免疫反应。
Purinergic Signal. 2024 Aug;20(4):321-343. doi: 10.1007/s11302-023-09966-7. Epub 2023 Oct 16.
3
Rehabilitation of the P2X5 receptor: a re-evaluation of structure and function.
P2X5 受体的修复:对结构和功能的再评价。
Purinergic Signal. 2023 Jun;19(2):421-439. doi: 10.1007/s11302-022-09903-0. Epub 2022 Oct 24.
4
Synthesis of Sulfonamide Tethered (Hetero)aryl ethylidenes as Potential Inhibitors of P2X Receptors: A Promising Way for the Treatment of Pain and Inflammation.作为P2X受体潜在抑制剂的磺酰胺连接(杂)芳基亚乙基的合成:一种治疗疼痛和炎症的有前景的方法。
ACS Omega. 2021 Sep 16;6(38):25062-25075. doi: 10.1021/acsomega.1c04302. eCollection 2021 Sep 28.
5
Recommended tool compounds and drugs for blocking P2X and P2Y receptors.推荐用于阻断 P2X 和 P2Y 受体的工具化合物和药物。
Purinergic Signal. 2021 Dec;17(4):633-648. doi: 10.1007/s11302-021-09813-7. Epub 2021 Sep 2.
6
A novel P2X2-dependent purinergic mechanism of enteric gliosis in intestinal inflammation.一种新型 P2X2 依赖性嘌呤能机制在肠道炎症中的肠胶质增生。
EMBO Mol Med. 2021 Jan 11;13(1):e12724. doi: 10.15252/emmm.202012724. Epub 2020 Dec 17.
7
Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets.P2 和腺苷受体的药物化学:为多个靶点改编的常见支架。
Biochem Pharmacol. 2021 May;187:114311. doi: 10.1016/j.bcp.2020.114311. Epub 2020 Oct 29.
8
Update of P2X receptor properties and their pharmacology: IUPHAR Review 30.P2X 受体特性及其药理学更新:国际药理学联合会评论 30.
Br J Pharmacol. 2021 Feb;178(3):489-514. doi: 10.1111/bph.15299. Epub 2020 Dec 21.
9
Development of Anthraquinone Derivatives as Ectonucleoside Triphosphate Diphosphohydrolase (NTPDase) Inhibitors With Selectivity for NTPDase2 and NTPDase3.蒽醌衍生物作为对核苷三磷酸二磷酸水解酶2(NTPDase2)和核苷三磷酸二磷酸水解酶3(NTPDase3)具有选择性的胞外核苷三磷酸二磷酸水解酶(NTPDase)抑制剂的研发。
Front Pharmacol. 2020 Aug 27;11:1282. doi: 10.3389/fphar.2020.01282. eCollection 2020.
10
To Inhibit or Enhance? Is There a Benefit to Positive Allosteric Modulation of P2X Receptors?抑制还是增强?P2X受体的正向变构调节有益处吗?
Front Pharmacol. 2020 May 12;11:627. doi: 10.3389/fphar.2020.00627. eCollection 2020.